To determine whether ANGPTLs are associated with sorafenib sensitivity in RCCs, we examined the mRNA expression levels of ANGPTL1-8 in 7 RCC cell lines (Fig. 1a and Supplementary Figure 1A), as well as a set of pre-treated tumour tissues from a cohort of RCC patients that presented with distinct responses to sorafenib therapy (Fig. 1b, Supplementary Figure 1B, Supplementary Table 1). This evidence concerns the gene ANGPTL1 and neoplasm.